Overdiagnosis of Alzheimer’s disease poses a genuine risk to patients who may receive a dementia diagnosis they don’t actually have—leading to years of unnecessary medication, lifestyle changes, and psychological distress based on a misidentification. When screening tools or biomarker tests flag someone as having Alzheimer’s pathology without clear cognitive decline, that person can be swept into a clinical category they may never progress to or experience, fundamentally altering their self-image and medical trajectory. A 68-year-old woman with early amyloid accumulation in her brain but no memory loss might be told she has Alzheimer’s disease and immediately prescribed donepezil, enrolled in cognitive monitoring programs, and encouraged to inform family members of a neurodegenerative diagnosis—all based on biology alone, not on functional reality.
The distinction matters because Alzheimer’s disease, by its clinical definition, includes both pathology and symptoms. Not everyone with amyloid plaques and tau tangles in the brain will develop cognitive impairment, and some may never decline noticeably in their remaining lifespan. Yet modern diagnostic frameworks—particularly the 2018 NIA-AA criteria that allow diagnosis based on biomarkers alone—have expanded who gets labeled as having the disease, catching both true cases and false positives. This shift has created a category of people living as patients without necessarily being symptomatic patients, and the fallout extends beyond the individual to family planning, employment, insurance, and daily decision-making.
Table of Contents
- How Screening Tools and Biomarkers Can Create Overdiagnosis in Alzheimer’s Disease
- The Cascade of Medical Interventions That Follow an Overdiagnosis
- How Overdiagnosis Affects Family Relationships and Life Planning
- Weighing Early Detection Against the Burden of Knowing and Living With Uncertainty
- The Challenge of Asymptomatic to Symptomatic Progression and the Variability in Cognitive Decline
- Cognitive Bias and the “Disease Label Effect” in Patient Perception
- The Role of Individual Risk Factors and Protective Factors in Personalizing Overdiagnosis Risk
How Screening Tools and Biomarkers Can Create Overdiagnosis in Alzheimer’s Disease
screening tools designed to catch early Alzheimer’s pathology are highly sensitive—meaning they are good at detecting biological changes—but sensitivity and specificity are different goals. A blood test that identifies phosphorylated tau or amyloid beta can flag someone as having Alzheimer’s pathology, but that same test will identify the pathology in cognitively normal people who may never experience symptoms. A study of cognitively normal older adults found that approximately 30 percent had amyloid positivity on PET imaging, yet only a fraction would develop cognitive decline within a decade. Screening casts a wide net, and the wider the net, the more people are caught who don’t match the disease’s functional definition.
The problem deepens when doctors or patients interpret a positive biomarker as a diagnosis rather than as risk information. When someone receives the result “amyloid positive” alongside a clinical diagnosis of “mild cognitive impairment due to Alzheimer’s disease,” they may not fully understand that they have no diagnosed cognitive impairment—only biology that suggests increased risk. The language of diagnosis carries weight, and a person told they have Alzheimer’s disease will live under that umbrella of expectation even if their cognition remains stable for years. Counseling and informed consent become critical, but many primary care settings lack the time and expertise to disambiguate between biomarker positivity, preclinical disease, and actual symptomatic cognitive decline.
The Cascade of Medical Interventions That Follow an Overdiagnosis
Once someone is diagnosed with Alzheimer’s disease—even in a preclinical or asymptomatic stage—they enter a treatment pathway that may include disease-modifying monoclonal antibodies, cholinesterase inhibitors, or memantine. These medications carry side effects: amyloid-lowering antibodies like lecanemab can cause amyloid-related imaging abnormalities (ARIA), including brain microhemorrhages and microinfarcts that may or may not be clinically significant but require ongoing MRI surveillance. For a person who will never develop symptoms, the downstream burden of medication management, infusion appointments, and neuroimaging is an unnecessary cost—both financial and psychological. The medical system also shifts into monitoring mode.
A preclinically diagnosed patient may be scheduled for neuropsychological testing, cognitive screening at every visit, and annual or semi-annual MRIs. Each test carries the implicit message that decline is expected, and over time, normal age-related fluctuation in memory or processing speed can be misinterpreted as disease progression. A person who forgets a friend’s name once and has heard they have Alzheimer’s disease may interpret that normal memory slip as confirmation of decline, introducing nocebo effects—where the belief in disease worsens subjective experience or actual cognitive performance. The psychological burden of living as an Alzheimer’s patient without the disease can itself impair quality of life and increase stress-related cognitive issues.
How Overdiagnosis Affects Family Relationships and Life Planning
Telling a family that a cognitively normal parent has Alzheimer’s disease reshapes family expectations and dynamics. Adult children may begin treating a parent differently—offering unsolicited help, questioning financial decisions, or limiting responsibilities—based on a diagnosis that has no behavioral or functional basis yet. A 70-year-old man diagnosed with preclinical Alzheimer’s after a positive amyloid scan may find his family assuming he will decline, when in fact he may live another 20 years with stable cognition. The diagnosis creates a false timeline in the family’s mind.
Life planning becomes complicated. Someone diagnosed with Alzheimer’s disease may feel pressured to retire early, hand over finances, or move to assisted living in anticipation of decline that may not occur. Relationships with spouses and partners can shift from equal partnership toward caregiver roles before any caregiving is needed. Insurance companies and long-term care facilities may use an Alzheimer’s diagnosis as grounds for higher premiums or enrollment restrictions, even if the person has no cognitive impairment. These real-world consequences flow from a label that reflects biology but not yet disease.
Weighing Early Detection Against the Burden of Knowing and Living With Uncertainty
The argument for early detection is straightforward: catching Alzheimer’s disease before symptoms appear offers the best window for disease-modifying treatment, and individuals can make informed choices about their futures while still cognitively intact. If someone will develop symptomatic Alzheimer’s disease, knowing sooner allows for planning, medication initiation, and family discussions while the person retains full decision-making capacity. For people at highest risk—those with a family history, genetic variants like APOE4, or measurable cognitive decline—this information may be genuinely valuable.
Yet for the substantial portion of people who are biomarker-positive but will remain cognitively stable, early detection trades the gift of years lived without the disease for years lived under the disease’s shadow. Studies on “worried well” populations show that people given risk information they cannot act on—information that may not come to pass—report persistent anxiety, reduced quality of life, and behavioral changes. The burden of uncertainty, combined with the social identity of being a dementia patient, may outweigh any benefit from early monitoring. This is a genuine tradeoff, and it is not resolved by better imaging or more sensitive biomarkers alone; it requires clarity about what diagnosis means and honest conversations about the likelihood of progression for that individual.
The Challenge of Asymptomatic to Symptomatic Progression and the Variability in Cognitive Decline
One of the strongest arguments against treating all biomarker-positive individuals as having Alzheimer’s disease is that the progression from pathology to symptom is highly variable and often stalled. Longitudinal studies following cognitively normal people with amyloid accumulation show annual cognitive decline rates of approximately 0.1 to 0.3 percent per year—much slower than the 3 to 4 percent annual decline observed in people with symptomatic mild cognitive impairment. Many amyloid-positive people will not reach clinical symptom threshold within their remaining lifespan, particularly if they are older at the time of discovery.
Age itself is a critical modifier. A 55-year-old with amyloid accumulation has a much higher risk of eventual cognitive decline than an 85-year-old with the same pathology, simply because the 85-year-old has fewer years for disease to develop. Overdiagnosis inflates rates most strikingly in older populations, where screening casts a wide net across people who are less likely to decline before natural lifespan endpoints. The danger lies in applying a preclinical diagnosis uniformly without stratifying risk, which means some people are alarmed and treated for a disease that will never become symptomatic in them.
Cognitive Bias and the “Disease Label Effect” in Patient Perception
Once someone carries a diagnosis of Alzheimer’s disease, cognitive science research shows that both the individual and people around them interpret ambiguous symptoms through a disease lens. A moment of distraction becomes “memory loss,” a delayed word recall becomes “cognitive decline,” and a normal mood dip becomes “depression from Alzheimer’s.” This interpretive bias is called the disease label effect, and it can artificially elevate symptom reporting and lower perceived cognitive competence. People with an Alzheimer’s diagnosis who perform identically on objective cognitive tests to age-matched controls without the diagnosis often rate their own cognitive function as worse, suggesting the diagnosis itself changes how people perceive and report their abilities.
For someone living with overdiagnosis, this bias translates to years of misinterpreted normal aging. A 72-year-old diagnosed with preclinical Alzheimer’s may struggle to remember where she placed her keys and immediately interpret this as disease progression, when in fact key misplacement is statistically normal in her age group. The diagnosis becomes a narrative lens that organizes experience, and it is difficult to separate the “real” effects of a disease process from the psychological and social effects of carrying a disease label.
The Role of Individual Risk Factors and Protective Factors in Personalizing Overdiagnosis Risk
Not all amyloid positivity is created equal, and neither is all overdiagnosis risk. Someone with amyloid accumulation, an APOE4 genetic variant, a family history of early dementia, and measurable (though mild) cognitive decline on testing is at significantly higher risk of developing symptomatic Alzheimer’s disease than someone who is amyloid-positive but cognitively normal, APOE4 negative, and with no family history. Yet screening protocols and diagnostic frameworks often treat all amyloid-positive individuals similarly, which means people at lowest risk of progression receive the same diagnostic label as people at highest risk.
Protective factors—cognitive reserve built through education and complex work, active social engagement, aerobic fitness, and Mediterranean-style diet adherence—also modify progression risk but are rarely quantified in diagnostic discussions. A 70-year-old with a PhD, an active consulting career, and strong social ties who is amyloid-positive faces a much different trajectory than a same-aged person with fewer years of education and social isolation. Personalizing the overdiagnosis conversation to include these modifiers would mean some people receive biomarker information without a disease diagnosis, allowing them to pursue protective strategies without the burden of a diagnostic label. A retired accountant with amyloid accumulation but no cognitive decline might be better served by counseling about cognitive engagement and cardiovascular fitness than by a diagnosis of Alzheimer’s disease.
